AtriCure, Inc. (ATRC) SEC Filings & Earnings Calls
EquiReason read 11 AtriCure, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-07-27 — AtriCure reported strong Q2 2026 results with 12.8% revenue growth, gross margin expansion, and a return to profitability..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
27 Jul 202610-QAtriCure reported strong Q2 2026 results with 12.8% revenue growth, gross margin expansion, and a return to profitability.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $154M | +13% y/y |
| Gross profit · Q2-2026 | $119M | +17% y/y |
| Income (loss) from operations · Q2-2026 | $10M | |
| Net income (loss) · Q2-2026 | $9M | |
| Diluted net income (loss) per share · Q2-2026 | $0.18 | |
| United States revenue · Q2-2026 | $126M | +14% y/y |
| International revenue · Q2-2026 | $28M | +10% y/y |
| Open ablation revenue (US) · Q2-2026 | $41M | +12% y/y |
| Minimally invasive ablation revenue (US) · Q2-2026 | $6M | -23% y/y |
| Pain management revenue (US) · Q2-2026 | $27M | +28% y/y |
Risks flagged
PFA catheter competition
“Minimally invasive ablation sales declined during the quarter from continued reduction in Hybrid procedures as physicians adopt PFA catheters to treat patients.” · word for word
SentreHEART litigation
“The amended complaint seeks damages in the amount of the original PMA and CPT reimbursement milestones of up to $ 260,000 plus interest.” · word for word
Increasing competition
“We have limited competition today; however, our key markets are attracting competition from new entrants developing competing products, procedures, and/or clinical solutions.” · word for word
23 Jul 20268-K · 2.02Q2 2026 revenue $153.6M (+12.8% YoY), net income $9.0M vs loss, adjusted EBITDA $27.3M (+78%), gross margin 77.2% (+269bps). FY2026 guidance raised: revenue $602-610M, adj. EBITDA $85-89M.earningsopen
Figures in the filing · each found in the filing text
| Worldwide revenue · Q2-2026 | $154M | +13% y/y |
| U.S. revenue · US · Q2-2026 | $126M | +14% y/y |
| International revenue · International · Q2-2026 | $28M | +10% y/y |
| Gross profit · Q2-2026 | $119M | +17% y/y |
| Gross margin · Q2-2026 | 77.2% | |
| Income from operations · Q2-2026 | $10M | -256% y/y |
| Net income · Q2-2026 | $9M | |
| Adjusted EBITDA · Q2-2026 | $27M | +78% y/y |
| Basic and diluted net income per share · Q2-2026 | $0.18 | -238% y/y |
| Cash generation · Q2-2026 | $22M |
Guidance
FY2026 revenue ~$602-610M; FY2026 adjusted EBITDA ~$85-89M; FY2026 net income per share $0.05-0.13; FY2026 adjusted EPS $0.24-0.32; continued positive cash generation
Full year 2026 guidance raised: revenue $602-610M, adjusted EBITDA $85-89M, positive cash generation expected
Risks flagged
Dependence on clinical trial outcomes for future growth
“advancing our BoxX-NoAF and LeAAPS clinical trials towards data readouts” · word for word
Regulatory and reimbursement risks inherent in medtech
“Forward-looking statements mention regulatory clearances, third-party reimbursement”
Competition from drugs and catheter-based technologies
“competition from existing and new products and procedures, including the development of drugs or catheter-based technologies” · word for word
19 May 20268-K · 5.02, 5.07Shares authorized under 2023 Stock Incentive Plan (amended) 6,000,000; Shares authorized under 2018 ESPP (amended) 750,000open
Figures in the filing · each found in the filing text
| Shares authorized under 2023 Stock Incentive Plan (amended) · 2026-05-18 | 6,000,000 | |
| Shares authorized under 2018 ESPP (amended) · 2026-05-18 | 750,000 |
Risks flagged
Potential dilution from increased equity compensation shares.
“Increase in shares available for issuance under stock plans.”
6 May 202610-QRevenue $141M (+14% y/y); Net income (loss) $108,000.00; Gross margin 77.4open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $141M | +14% y/y |
| Net income (loss) · Q1-2026 | $108000.00 | |
| Gross margin · Q1-2026 | 77.4% | |
| Operating cash flow · Q1-2026 | $-4M | |
| US Revenue - Open ablation · US Open ablation · Q1-2026 | $39M | +17% y/y |
| US Revenue - Minimally invasive ablation · US Minimally invasive ablation · Q1-2026 | $6M | -25% y/y |
| US Revenue - Pain management · US Pain management · Q1-2026 | $22M | +30% y/y |
| US Revenue - Appendage management · US Appendage management · Q1-2026 | $48M | +15% y/y |
| International Revenue · International · Q1-2026 | $25M | +12% y/y |
| Cash and cash equivalents · 2026-03-31 | $146M |
Risks flagged
Competitive pressure from PFA catheters
“Minimally invasive ablation sales declined during the quarter from continued reduction in Hybrid procedures as physicians adopt PFA catheters to treat patients.” · word for word
Litigation risk from SentreHEART acquisition
“The amended complaint seeks damages in the amount of the original PMA and CPT reimbursement milestones of up to $260,000 plus interest.” · word for word
5 May 20268-K · 2.02Worldwide revenue $141M (+14% y/y); Net income $100,000.00; Adjusted EBITDA $17M (+95% y/y); Guidance: Revenue guidance $600-610M, adjusted EBITDA $80-82Mearningsopen
Figures in the filing · each found in the filing text
| Worldwide revenue · Q1-2026 | $141M | +14% y/y |
| Net income · Q1-2026 | $100000.00 | |
| Adjusted EBITDA · Q1-2026 | $17M | +95% y/y |
| Gross margin · Q1-2026 | 77.4% | |
| U.S. revenue · U.S. · Q1-2026 | $116M | +15% y/y |
| International revenue · International · Q1-2026 | $25M | +12% y/y |
| Gross profit · Q1-2026 | $109M | |
| Income from operations · Q1-2026 | $500000.00 | |
| Basic and diluted net income per share · Q1-2026 | $0.00 |
Guidance
Revenue guidance $600-610M, adjusted EBITDA $80-82M
Full year 2026 revenue guidance reaffirmed at $600-610M and adjusted EBITDA guidance at $80-82M, reflecting strong demand and margin expansion.
Risks flagged
Clinical trial outcomes and regulatory approvals are key risks; negative data could impact growth.
“Negative clinical data; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products.”
Competition from drugs or catheter-based technologies could erode market share.
“Competition from existing and new products and procedures, including the development of drugs or catheter-based technologies.” · word for word
Tariffs or restrictive trade measures could impact costs and supply chain.
“The impact of tariffs or other restrictive trade measures.” · word for word
Reliance on third-party manufacturers and suppliers poses supply chain risk.
“Reliance on third party manufacturers and suppliers.” · word for word
6 Apr 2026DEF 14AProxy statement filed for annual shareholder meeting; includes proposals to elect directors, ratify auditor, amend stock plans, and advisory vote on executive compensation.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $535M | +15% y/y |
| Gross Margin · FY2025 | 75.0% | |
| Adjusted EBITDA · FY2025 | $62M | +98% y/y |
17 Feb 20268-K · 2.02Worldwide revenue $140M (+13% y/y); Net income $2M; Adjusted EBITDA $20M; Guidance: FY2026 revenue guidance $600-610M (+12-14% YoY); adjusted EBITDA $80-82Mearningsopen
Figures in the filing · each found in the filing text
| Worldwide revenue · total · Q4-2025 | $141M | +13% y/y |
| Net income · total · Q4-2025 | $2M | |
| Adjusted EBITDA · total · Q4-2025 | $20M | |
| Worldwide revenue (FY) · total · FY2025 | $535M | +15% y/y |
| Net loss (FY) · total · FY2025 | $11M | |
| Adjusted EBITDA (FY) · total · FY2025 | $62M | +98% y/y |
| Gross margin · total · Q4-2025 | 75.0% | |
| U.S. revenue · U.S. · Q4-2025 | $114M | +13% y/y |
| International revenue · International · Q4-2025 | $26M | +15% y/y |
Guidance
FY2026 revenue guidance $600-610M (+12-14% YoY); adjusted EBITDA $80-82M
Management raised guidance with strong revenue growth and profitability improvement expected in 2026.
Risks flagged
Minimal risk; strong revenue growth, margin expansion, and positive guidance.
“No material risk factors highlighted in the release.”
12 Jan 20268-K · 1.01, 2.02, 2.03AtriCure amended its ABL Facility, extending term by 3 years, reducing interest rate, removing minimum utilization covenant, and maintaining $125M capacity with $40M accordion. Preliminary Q4/FY2025 revenue beat expectations, and FY2026 guiopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $141M | +13% y/y |
| Revenue · FY2025 | $535M | +15% y/y |
| U.S. Revenue · U.S. · Q4-2025 | $114M | +13% y/y |
| International Revenue · International · Q4-2025 | $26M | +15% y/y |
| Cash and Investments · Q4-2025 | $167M |
Guidance
2026 revenue guidance $600-610M, up 12-14%
Management provided 2026 guidance with 12-14% revenue growth, adjusted EBITDA of $80-82M, and expectation of net income.
Risks flagged
Debt and leverage from credit facility
“ABL Facility of up to $125 million; first amendment extended term and reduced interest rate.”
30 Oct 202510-QAtriCure reported Q3 2025 revenue of $134.3M (+15.9% YoY) and a net loss of $0.3M, significantly improved from a $7.9M loss in Q3 2024.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $134M | +16% y/y |
| Net loss · Q3-2025 | $-267000.00 | |
| Gross margin · Q3-2025 | 75.5% | |
| Operating cash flow · 9M-2025 | $37M | |
| Cash and cash equivalents · 2025-09-30 | $148M | |
| International revenue · Q3-2025 | $25M | +22% y/y |
| EPS · Q3-2025 | $-0.01 | |
| Revenue US · Q3-2025 | $109M | +15% y/y |
Risks flagged
Litigation risk from SentreHEART acquisition
“The amended complaint seeks damages in the amount of the original PMA and CPT reimbursement milestones of up to $260,000 plus interest.” · word for word
Competitive pressure from new entrants
“There are limited competitors in our key markets; however, new entrants are developing competing products, procedures, and/or clinical solutions that may cause variability in our results.” · word for word
29 Oct 20258-K · 2.02Revenue $134M (+16% y/y); net income $-300,000.00; adjusted ebitda $18M; Guidance: Revenue guidance raised to ~$532-534M from prior; Adjusted EBITDA raised to ~$55-57Mearningsopen
Figures in the filing · each found in the filing text
| revenue · Q3-2025 | $134M | +16% y/y |
| net_income · Q3-2025 | $-300000.00 | |
| adjusted_ebitda · Q3-2025 | $18M | |
| revenue_us · U.S. · Q3-2025 | $109M | +15% y/y |
| international_revenue · International · Q3-2025 | $25M | +22% y/y |
| gross_margin · Q3-2025 | 75.5% | |
| eps · Q3-2025 | $-0.01 |
Guidance
Revenue guidance raised to ~$532-534M from prior; Adjusted EBITDA raised to ~$55-57M
Raised full-year 2025 revenue and Adjusted EBITDA guidance based on strong Q3 performance.
Risks flagged
Dependence on product adoption and market acceptance.
“Risks include rate and degree of market acceptance of our products; competition from existing and new products and procedures.”
AtriCure, Inc. — questions
- What did AtriCure, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 10-Q on 2026-07-27 — AtriCure reported strong Q2 2026 results with 12.8% revenue growth, gross margin expansion, and a return to profitability.
Every figure on this page comes from AtriCure, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.